Advanced search×

Cancer photothermal therapy in the near-infrared region by using single-walled carbon nanotubes.

J Biomed Opt 14(2):021009 (2009) PMID 19405722

Single-walled carbon nanotubes (SWNTs) have a high optical absorbance in the near-infrared (NIR) region. In this special optical window, biological systems are known to be highly transparent. The optical properties of SWNTs provide an opportunity for selective photothermal therapy for cancer treatment. Specifically, CoMoCAT nanotubes with a uniform size (about 0.81 nm) and a narrow absorption peak at 980 nm are ideal candidates for such a novel approach. Here, CoMoCAT SWNTs are conjugated to folate, which can bind specifically to the surface of the folate receptor tumor markers. Folate-SWNT (FA-SWNT) targeted tumor cells were irradiated by a 980-nm laser. In our in vitro and in vivo experiments, FA-SWNT effectively enhanced the photothermal destruction on tumor cells and noticeably spared the photothermal destruction for nontargeted normal cells. Thus, SWNTs, combined with suitable tumor markers, can be used as novel nanomaterials for selective photothermal therapy for cancer treatment.

DOI: 10.1117/1.3078803
Version: za2963e q8zaf q8zbf q8zcf q8zdd q8ze2 q8zf6 q8zgc

Similar articles you may find interesting…

  1. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.

    Genes Chromosomes Cancer (2013) PMID 23650027

    The serine/threonine-protein kinase B-raf (BRAF) is an oncogene mutated in various neoplasms, including 5-15% of colorectal carcinomas. The T1799A point mutation, responsible for a large majority of these alterations, results in an amino acid substitution (V600E) causing the constitu...
  2. Molecular targeted agents (MTA) combination therapy for cancer: Developments and potentials.

    Int J Cancer (2013) PMID 23649791

    We summarize the clinical and preclinical studies that are underway in an attempt to improve the anticancer efficacy of chemotherapies through combination strategies. Studies of combining cytotoxic agents with molecular targeted agents, co-inhibiting two or more targets in a single pathway, or co-in...
  3. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.

    Clin Cancer Res (2013) PMID 23649003

    Seventy-four of 113 (65.4%) and 24 of 71 (33.8%) were progression free after 4 cycles of CD and EP, respectively. Median overall survival (OS) was 16 months (95% CI, 13.6-19.0 months). Of the 7 "anaplastic" criteria, bulky tumor mass was significantly associated with poor outcome. Lactic acid dehydr...